Financial News

Financial Report: Amgen

Growth was offset by declines for flagship products

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Amgen 3Q Revenues: $5.7 billion (-3%) 3Q Earnings: $2.0 billion (+6%) YTD Revenues: $17.2 billion (-2%) YTD Earnings: $6.1 billion (-5%)   Comments: Enbrel sales were $1.4 billion in the quarter, up 6%. Prolia sales were up 18% to $630 million. Repatha sales were up 40% to $168 million. Aimovig sales totaled $66 million in the quarter. Parsabiv sales were up 54% to $157 million. KYPROLIS sales were $266 million, up 15%. BLINCYTO sales were up 47% to $85 million. Growth was offset by decline...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters